Event Calendar

Master class All Events

Epilepsy and infection during pregnancy and the peripartum period

Developed by: UKCPA Women’s Health Group

Date

09, Jun 2017

Location

Royal Pharmaceutical Society
66-68 East Smithfield
London
E1W 1AW

£ Prices

Member Price: £130
Non-Member Price: £199

Book Now
RPS Accredited Training Provider
09
Jun

Overview

This event is aimed at both core advanced and specialist pharmacists with an interest in epilepsy and infection management in pregnancy.

The day will cover aspects of epilepsy and infection during pregnancy and the peripartum period. This will include the management of anti-epileptic drugs during pregnancy, the obstetric risks to women with epilepsy and the risks to the foetus and newborn resulting from exposure to anti-epileptic drugs, and the management of epileptic seizures during pregnancy and in labour.

It will also cover the identification and management of maternal and neonatal sepsis, the management and pharmacological treatment of HIV positive women during pregnancy and the peripartum period, the implications of HIV diagnosis on obstetric and neonatal management, and the risks to the foetus and newborn from exposure to anti-retrovirals.

Attending this event will help you advance your professional practice and could be used as evidence in your RPS Faculty portfolio.

Target audience

  • Pharmacists working at advanced level with an interest in epilepsy or infection management, including sepsis and HIV, in pregnancy
  • Pharmacists specialising in women’s health, infection or neurosciences
  • Pharmacists specialising in infection management
  • Pharmacists specialising in neurosciences
  • Pharmacists specialising in HIV

Learning outcomes

Epilepsy in pregnancy

At the end of this event, participants should be able to:

  • Develop an understanding of the types of epilepsy in the general population and the implications of pregnancy on management of the condition; be able to differentiate between seizures due to epilepsy and that of other origin such as pre-eclampsia in pregnancy.
  • Describe the pharmacological and pharmacokinetic changes in drug handling of anti-epileptic drugs as a result of pregnancy, including an understanding of dosing and monitoring requirements for anti-epileptic drugs during the antenatal and peripartum period and how these may change as the pregnancy progresses.
  • Demonstrate an understanding of obstetric risks to women with epilepsy, risks to foetus and newborn resulting from exposure to anti-epileptic drugs, importance of pre-pregnancy counselling and strategies to reduce risk both during pregnancy and whilst breastfeeding.
  • Demonstrate knowledge of commonly used drugs in pregnancy that need to be viewed in light of the diagnosis
  • Demonstrate awareness of optimum management of epileptic seizures during pregnancy and in labour.
  • Demonstrate an understanding of the considerations of suitable contraceptive methods for women with epilepsy.

Sepsis in pregnancy

At the end of this event, participants should be able to:

  • Demonstrate an understanding of the risks of infection during pregnancy and strategies to reduce risk.
  • Demonstrate knowledge of the main infections occurring during pregnancy, at delivery and post-partum.
  • Demonstrate understanding of symptoms and signs of maternal sepsis and how to identify and monitor for these.
  • Demonstrate knowledge of the use of antimicrobials for caesarean section or gynaecological surgery including management of surgical site infections and surgical prophylaxis.
  • Demonstrate knowledge of pharmacological management of commonly incurred infections in pregnancy and in the peripartum period, taking into consideration the risks to the foetus and newborn.
  • Demonstrate knowledge of pre-emptive treatment of potential infections in the newborn.
  • Understand pathophysiology and risk factors for the development of neonatal sepsis (early and late onset), particularly Group B Streptococcus.
  • Understand the mechanism of action, pharmacology and pharmacokinetic characteristics and clinical use of treatments for neonatal sepsis.
  • Demonstrate knowledge of dosing and monitoring requirements in pregnancy and in the newborn of antimicrobials with a narrow therapeutic index.

HIV in pregnancy

At the end of this event, participants should be able to:

  • Develop an understanding of the diagnosis, management and pharmacological treatment of human immunodeficiency virus (HIV) positive women during pregnancy and the peripartum period including late presenting women not on treatment; demonstrate knowledge of commonly used antiretroviral protocols in this group.
  • Demonstrate awareness of the British HIV Association guidelines for management of women in pregnancy.
  • Demonstrate knowledge of the implications of HIV diagnosis on obstetric management
  • Demonstrate knowledge of the implications of HIV diagnosis on neonatal management.
  • Demonstrate an understanding of risks to foetus and newborn from exposure to anti-retrovirals.
  • Demonstrate knowledge of contraceptive choices for women with HIV including awareness of transmission and drug interaction issues.